HEC169096 in Participants With Advanced Solid Tumors
A phase 1/2 trial of HEC169096 in advanced solid tumours, run by Sunshine Lake Pharma Co., Ltd., now recruiting.
Overview
HEC169096 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05451602 by Sunshine Lake Pharma Co., Ltd., with 456 participants planned, started 2022-10-21 and due to reach its primary completion in 2026-12-30. Interventions recorded: HEC169096.
Similar pages
not linked directly; found by shared links- TrialA Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
- TreatmentLerotinib
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.